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Background: Dengue disease surveillance and vector surveillance are presumed to detect dengue outbreaks at an early
stage and to save – through early response activities – resources, and reduce the social and economic impact of outbreaks
on individuals, health systems and economies. The aim of this study is to unveil evidence on the cost of dengue outbreaks.
Methods: Economic evidence on dengue outbreaks was gathered by conducting a literature review and collecting
information on the costs of recent dengue outbreaks in 4 countries: Peru, Dominican Republic, Vietnam, and Indonesia.
The literature review distinguished between costs of dengue illness including cost of dengue outbreaks, cost of
interventions and cost-effectiveness of interventions.
Results: Seventeen publications on cost of dengue showed a large range of costs from 0.2 Million US$ in Venezuela to
135.2 Million US$ in Brazil. However, these figures were not standardized to make them comparable. Furthermore, dengue
outbreak costs are calculated differently across the publications, and cost of dengue illness is used interchangeably with
cost of dengue outbreaks. Only one paper from Australia analysed the resources saved through active dengue
surveillance. Costs of vector control interventions have been reported in 4 studies, indicating that the costs of such
interventions are lower than those of actual outbreaks. Nine papers focussed on the cost-effectiveness of dengue vaccines
or dengue vector control; they do not provide any direct information on cost of dengue outbreaks, but their modelling
methodologies could guide future research on cost-effectiveness of national surveillance systems.
The country case studies – conducted in very different geographic and health system settings - unveiled rough estimates
for 2011 outbreak costs of: 12 million US$ in Vietnam, 6.75 million US$ in Indonesia, 4.5 million US$ in Peru and 2.8 million
US$ in Dominican Republic (all in 2012 US$). The proportions of the different cost components (vector control; surveillance;
information, education and communication; direct medical and indirect costs), as percentage of total costs, differed across
the respective countries. Resources used for dengue disease control and treatment were country specific.
Conclusions: The evidence so far collected further confirms the methodological challenges in this field: 1) to define
technically dengue outbreaks (what do we measure?) and 2) to measure accurately the costs in prospective field studies
(how do we measure?). Currently, consensus on the technical definition of an outbreak is sought through the
International Research Consortium on Dengue Risk Assessment, Management and Surveillance (IDAMS). Best practice
guidelines should be further developed, also to improve the quality and comparability of cost study findings. Modelling
the costs of dengue outbreaks and validating these models through field studies should guide further research.
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Dengue is geographically a fast-spreading disease (WHO
2012) [1]. Outbreaks hit the economy and health sys-
tems of endemic countries with variable epidemiologic
magnitude. Resources used for the prevention and treat-
ment of dengue are not available for alternative uses in
health systems or in the economy as a whole. Dengue is
in competition with other diseases for the limited re-
sources available, especially in endemic countries with
dengue-outbreaks, where too there are efforts to bring
the costs of dengue interventions within the reach of less
wealthy populations. Health technologies available to re-
duce the consumption of resources used to prevent and
treat dengue are therefore of high interest, since re-
sources saved can be allocated to other diseases and sec-
tors of the economy. Investigations on the efficacy of
health technologies to combat dengue are nowadays al-
ways supplemented by health economic analyses.
As a first step, this paper reviews available literature on
cost of dengue outbreaks worldwide. As a second step,
country case studies are used to gather first-hand evidence
on the direct costs of dengue outbreaks in 2011 in four se-
lected countries: two countries in the Americas (Peru and
Dominican Republic) and two countries in South East
Asia (Vietnam and Indonesia). The ultimate aim, which is
not part of this technical report, is to appraise the effi-
ciency of improved surveillance.
Beatty et al. (2011) [2] reviewed the methodology used
in the health economic literature on dengue from 1966 to
2009. Although the publication did not focus on reviewing
the actual costs of dengue, it classified systematically the
available health economic dengue literature. Shepard et al.
(2011) [3] estimated the cost of the dengue illness in all
the countries in The Americas combined to be about 2.1
billion US$ on average per year. Comparable figures for
the Asian region were missing at the time of literature re-
view, but have recently been calculated by Shepard et al.
(2013) [4]. The present paper aims at reviewing all avail-
able published evidence on cost of dengue outbreaks inde-
pendently of the methodology employed to calculate these
costs. Despite the absence of a unanimous technical defin-
ition of a dengue outbreak, the paper aims to introduce a
distinction between cost of dengue outbreaks and cost of
dengue illness studies. Cost-of-illness implicitly calculates
the opportunity cost of an illness versus a theoretical situ-
ation where the disease has been eliminated.
The rationale of this research is to provide ministries or
official institutions in dengue-endemic countries with evi-
dence on the costs of dengue outbreaks, so as to guide
them on the expected returns on their investments in sur-
veillance systems tailored to identify, respond to and stop
potential dengue outbreaks at an early stage. The under-
lying assumption was that by showing the costs of a den-
gue outbreak, governments would be more inclined to putresources into outbreak prevention, early outbreak detec-
tion and response.
Besides the practical difficulties in ascertaining costs of
dengue outbreaks in the field, the costing of dengue out-
breaks is problematic in several other respects: i) the health
systems and the economy of countries are very different in
terms of their health systems’ structures and the resources
deployed to combat dengue. ii) there is no unique world-
wide dengue outbreak definition [5]; iii) the measurement
of how much of an outbreak could be avoided by certain
interventions might be ethically and practically impossible
to conduct in a prospective field study.
However, the aim of the literature review is to study
the publications on costs of dengue, with respect to: A)
how these dengue costs have been measured and B)
what were the findings in terms of cost of dengue.
Methods
Literature review
Search strategy
The literature review was conducted in the following da-
tabases: the United States National Library of Medicine
and the National Institutes of Health Medical Database
(PubMed) (1966–2012); the Cochrane Database of Sys-
tematic Reviews (CDSR); the World Health Organisation
(WHO) library database (WHOLIS) and the Latin
American and Caribbean Health Sciences Database (Li-
lacs) (1967–2012); Econlit; and the library of the Pan
American Health Organization (PAHO). The free text
search terms “cost” and “dengue” were used. All cita-
tions up to April 1st 2012 were included, irrespective of
language or publication year.
We identified 220 citations out of which we selected 56
eligible abstracts according to the following criteria: A)
analysed cost; B) provided detailed methods; C) included
data analysis. Out of these selected abstracts we identified
12 duplicates and 3 papers that were not accessible to us.
Finally, 41 citations were selected for full text review. Den-
gue cost studies were defined as analyses identifying, quan-
tifying and valuing in monetary terms those resources used
(direct medical, direct non-medical, and indirect) at any
stage of dengue disease prevention or control, on any geo-
graphical level (region, country, continent, world) from any
perspective (patient, relatives, government, provider or so-
cietal) at any level of intervention (vector, cases) and dis-
ease severity, including or excluding assessments of
effectiveness of health technologies. The rationale was to
collect as much information as possible from different pub-
lications, wherever costs were analysed in the context of
dengue, with the aim of compiling dengue outbreak costs.
Evidence level
The reliability of evidence of the papers was not assessed
in a thorough manner within the present review. Based on
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level of evidence of those studies prior to 2009 (Table 1).
Data extraction and synthesis
Two independent authors (VMB and HCS) assessed the
full texts. Consensus was achieved about inclusion and ex-
clusion criteria. Of the 41 studies, general information was
retrieved on the following categories: First Author, Publi-
cation, Publication Year, Countries, Cities, Study Period,
Intervention(s), Control, Randomized, Perspective, Out-
come, Subjects, Inclusion Criteria, Exclusion Criteria,
Total Cases, Cost Type, Cost Year, Currency, Cost Hori-
zon, Costs, Effect Type, Effect Year, Effect Horizon, Ef-
fects, Remarks. In a second-round review, studies were
excluded that met the following criteria:
1. reviews of already published original publications
2. analyses of the burden of disease in non-monetary
terms.
Publications were then classified in different groups
depending on the aim of cost collection:
A. cost of dengue illness or cost of dengue outbreaks
B. cost of intervention
C. cost-effectiveness of intervention
We analysed also studies that included cost of inter-
ventions, since our final interest is to assess the
cost-effectiveness of surveillance systems. The flow
chart of the literature review process is represented in
Additional file 1: Figure S1.
The literature review was protocoled according to the
PRISMA checklist given in Additional file 2: Table S1.Table 1 Evidence score of publications reviewed (see
Beatty et al. (2011) [2])
Quality
score
Description
I Evaluation of important alternative interventions
comparing all clinically-relevant outcomes against appro
priate cost measures, and including a clinically-relevant
sensitivity analysis
II Evaluation of important alternative interventions
comparing a limited number of outcomes against
appropriate cost measurement, but including a clinically-
sensible sensitivity analysis
III Evaluation of important alternative interventions
comparing all clinically-relevant outcomes against inappro
priate cost measurement, but including a clinically-sensible
sensitivity analysis
IV Evaluation without a clinically-sensible sensitivity analysis
V Expert opinion with no explicit critical appraisal, based on
economic theory
UE Ungraded evidenceCountry case studies on costs of dengue outbreaks
Collection of costs
The perspective taken in this field-study cost collection
was societal, based on a mixture of micro- and macro-
costing data collection. The aim was to calculate the aver-
age treatment costs of a dengue patient based on a micro-
costing approach, and multiply the costs by the number of
cases during the outbreak. Indirect costs were not col-
lected because, in the context of this study, the interest
was focussed on the costs for health services and their ad-
ministration. Expansion factors were not used. Surveillance
systems might under- or over-report the total number of
cases. These numbers may be corrected by multiplying re-
ported cases by an expansion factor (EF).
Resource consumption in medical care was collected
in hospital settings by contacting interviewers in four
dengue-endemic countries, which had experienced re-
cent dengue outbreaks: Dominican Republic, Peru,
Indonesia, and Vietnam. The countries were selected
by the Special Programme for Research and Training in
Tropical Diseases at the World Health Organization in
Geneva (TDR-WHO) and by the WHO Regional offices
PAHO and SEARO. In each country a data collector
was hired with background in public health and some
training in economics. The country interviewers received
the research protocol, detailed instructions about how to
proceed, and a data collection form for costing individual
patients. In each country, the interviewers collected
data from 5 to 10 dengue patients with the pre-defined
form in different health service settings and categories:
outpatients, children in-patients, adult in-patients, chil-
dren in intensive care units, adults in intensive care units.
The interviewers collected data through document ana-
lysis (clinical histories of patients in the different treat-
ment categories) and interviews with key informants. The
latter included: dengue clinicians, to establish the typical
treatment and required resources for a dengue patient; la-
boratory staff, to complement the information of the clin-
ician; pharmacy staff, to establish the cost of each item;
chief entomologist or vector control manager and staff in
the communications department.
Data analysis
Through the above step-wise approach, the typical treat-
ment and average treatment costs per patient in the differ-
ent patient categories were established. On the basis of
the patient samples, averages were calculated for the fol-
lowing categories: laboratory; technical services; drugs;
consumables; fees; and other resources. The sum of these
categories was the total treatment cost per patient derived
from our sample for the respective treatment setting. The
average direct medical cost per patient without personal
costs was derived by multiplying the total costs per patient
in each treatment setting by the number of patients during
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the different settings, and dividing by the total number of
reported patients during the outbreak. Additionally, the in-
terviewers collected information from national sources on
expenditures for vector control, surveillance, information,
education and communication during the most recent
outbreak.Ethical aspects
Exemption from ethical approval was granted by WHO
Regional Offices based on the fact that no direct individ-
ual information was collected. However, each respondent
signed an informed consent form.Results
Systematic literature review
Publications on cost of dengue illness and cost of dengue
outbreaks (group A)
In total 17 publications met the inclusion criteria. All but
2 publications collected primary data, and most studies
took a societal perspective without indicating it explicitly.
Of the 17 publications, 5 [6-10] intentionally narrowed
the perspective to the impact of dengue illness at the
household level. Of these household studies, two were
conducted in Cambodia, two in Thailand and one in
Vietnam. The average cost of dengue illness per patient
ranged from 16.6 US$ [6] for children at primary school
to 24 US$ per family in Thailand [7], from 31.5 US$ for
households with children aged <15 years [10] to 32 US$
for households treated in public and private hospitals in
Cambodia [8] and 61.3 US$ for children with dengue
haemorrhagic fever (DHF) in Vietnam [9].
Out of the 17 publications, 2 used modelling, with a
mixture of primary and secondary data, to assess the cost
of illness in India [11], and for all the countries in the
Americas [3]. Both of these included costs that were dir-
ect, indirect, and due to fatal cases, but not costs related
to vector control, surveillance, and information, education
and communication. The total economic dengue burden
in India was estimated to be 27.4 million US$ compared
to 2.1 billion US$ in the Americas.
Only one study [12], conducted in Cuba, was designed
as a prospective study comparing, in a non-endemic den-
gue region of Cuba, a period of no transmission with a
period of transmission, so as to calculate the incremental
cost of a dengue outbreak. The total economic cost per in-
habitant per month was around 2.7 US$ in months with-
out transmission versus 6 US$ in outbreak periods. The
population and the health care system largely incurred the
cost increments, but hardly any of the costs of the vec-
tor control programme, which are usually fixed costs.
The average cost per hospitalised dengue case was
296.60 US$ in Cuba.With the exception of the incremental approach in the
Baly et al. 2012 study [13], the method chosen to calculate
the total cost of dengue outbreaks is to multiply the num-
ber of reported cases by an expansion factor (ratio of ob-
served to reported cases) and by the average cost per case
(direct and indirect costs) and to add the surveillance, vec-
tor control, information, education and communication
budgets of the communities and the central governments
(where applicable). The terminology ‘cost of dengue out-
break’ and ‘cost of dengue illness’ are often used as syno-
nyms. An unambiguous definition of ‘cost of dengue
outbreak’ is currently missing, although Baly et al. 2012
[13] suggested an alternative way to calculate incremental
outbreak costs.
Out of the 17 publications, 9 covered the cost of den-
gue illness with differing degrees of evidence regarding
their primary data collection: Cambodia [14], Cuba
[15,16], Venezuela [17], Panama [18], Australia [19],
Thailand [20], Americas & Asia [21] and Puerto Rico
[22]. Total cost of dengue illness for Cambodia [14]
ranged from 3.3 million US$ to 14.4 million US$ de-
pending on the year considered (2007–2008) and the
cost of dengue cases ranged from 27 US$ to 75 US$,
including direct and indirect costs. In Cuba, total cost
of dengue illness ranged from 10.3 million US$ in 1997
[16] to 103.2 million US$ in 1981 [15]. In Thailand, the
1994 total dengue cost was estimated to be 12.6 million
US$. The indirect and direct cost per dengue case in
Bangkok amounted to 161.5 US$ for an adult and
118.3 US$ for a child. In Panama the 2005 outbreak in-
duced total costs of 16.9 million US$ (5.2 US$ per
capita) including direct and indirect costs and govern-
ment spending on dengue control efforts [18]. A publi-
cation on the cost of dengue illness between 1997–
2003 in Venezuela reported total costs of 1.4 million
US$ [17] for that period. The first study form 1977, of
cost of dengue illness in Puerto Rico estimated total
costs to vary between 6 to 15.6 million US$ [22] de-
pending on the attack rate of mosquitoes. Suaya et al.
[21] estimated the aggregate annual cost of dengue
illness in the Americas, covering Brazil (135.2 million
US$), El Salvador (1.7 million US$), Guatemala (1.2
million US$), Panama (0.9 million US$) and Venezuela
(10.2 million US$) to be about 149.3 million US$ based
on incidence for the years 2001 to 2005 and primary
data collected from 1,160 patients. Suaya [21] esti-
mated the aggregate annual cost of dengue illness for
Asia, covering Cambodia (2.8 million US$), Malaysia
(38.2 million US$) and Thailand (47.8 million US$), to
be about 88.8 million US$ based on the 2001–2005 re-
ports and on primary data collected for 535 patients in
total. For Australia, Canyon [19] estimated total annual
dengue illness costs to be about 2.7 million US$ per
year since 1990.
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Figure 1 Cost components during dengue outbreaks in Vietnam. All in US$ of the year 2011; Vector control: 5,285,280 US$ (44%);
Surveillance: 1,029,600 US$ (9%); IEC: 549,120 US$ (5%); Direct cost: 2,700,138 US$ (22%); Indirect cost: 2,447,000 US$ (20%).
Stahl et al. BMC Public Health 2013, 13:1048 Page 5 of 11
http://www.biomedcentral.com/1471-2458/13/1048Publications on cost of interventions (group B)
We identified 4 studies calculating the cost of interven-
tions: one in Vietnam on community-based strategies
against the vector Aedes aegypti [23], one in Venezuela
and Thailand on the cost of routine aedes aegypti con-
trol and insecticide-treated curtain implementation [24],
one in Australia on costs of cutting mosquito surveil-
lance budgets [25] and one in Brazil on the direct costs
of dengue prevention and control programs [26].
For Australia, Vazquez-Prokopec et al. [25] showed the
effect of delayed response to dengue outbreaks of 4 to 6
weeks, which would result in 86 times (or 13 million US
$ in 2003) and 346 times (or 382 million US$ in 2009)
higher dengue illness costs versus a scenario with activeTable 2 Typical direct medical cost of a dengue patient,
by treatment setting without personal cost, in Indonesia
Treatment setting Typical cost (US$) Typical cost (Rupiah)
Outpatient (<15 years) 50,080 5
Outpatient (>15 years) 52,870 6
General ward (<15 years) 958,715 101
General ward (>15 years) 2,353,683 247
ICU (<15 years) 17,637,762 1,852
ICU (>15 years) 5,618,929 590surveillance and response within 2 weeks. Their calcula-
tions suggest the value of an active and fast dengue sur-
veillance and response system. The calculations of Baly
et al. [12] of the costs of control programs in one state
in Venezuela (0.38 million US$) and in one province in
Thailand (0.08 million US$) and of Kay et al. [23] for
Vietnam also suggest the low cost of dengue control
measures compared to the cost of uncontrolled dengue
outbreaks. Taliberti et al. [26] estimate the cost of den-
gue prevention and control in Sao Paolo in 2005 to be
12.5 million US$ (or 1.14 US$ per capita).
Publication on cost-effectiveness of interventions (group C)
Three publications out of the 9 in group C investigated the
cost-effectiveness of a dengue vaccine. Carrasco et al. [27]
investigated the cost-effectiveness of future vaccination
programs in Singapore, whereas Lee et al. [28] assessed the
economic value of a dengue vaccine in Thailand, and fi-
nally Shepard et al. [29] evaluated the cost-effectiveness of
a paediatric dengue vaccine.
Six publications assessed the cost-effectiveness of in-
terventions aimed at improving dengue vector control.
Alphey et al. [30] assessed the cost-effectiveness of
genetics-based sterile insect methods for vector con-
trol. Suaya et al. [31] investigated the cost-effectiveness
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Figure 2 Cost components during dengue outbreaks in Indonesia. All in US$ of the year 2011; Vector control: 465,676 US$ (7%); Surveillance:
13,722 US$ (0.2%); IEC: 2,927 US$ (0.04%); Direct cost: 3,288,168 US$ (48.7%); Indirect cost: 2,979,902 US$ (44%).
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compared vertical versus community-based approaches
in Cuba. McConnell et al. [32] focused on control pro-
grams in Puerto Rico, whereas Orellano et al. [33] ana-
lysed the cost-benefit of control programs versus no
control in Argentina. Luz et al. [34] developed an eco-
nomic model to assess dengue vector control strategies.
The modelling methods used for assessing the eco-
nomic value of vaccine intervention and the cost-
effectiveness of vector control programs might lead to
future research on the cost-effectiveness of national
surveillance systems.
The complete extraction matrix of the selected and
reviewed literature is given in the Additional file 3:
Table S2.
Country case studies
Vietnam
For Vietnam, a sample of patient records was collected
in one hospital, differentiating four groups of patients
comprising outpatients, those treated in the general
ward subdivided into adults and children (<15 years),
and patients in intensive care units (in this case, no dis-
tinction between adult and children was made as there
was no major cost difference). The analysis wasconducted on the basis of 2012 Vietnam Dong (VND)
and an exchange rate of 20,833 (VND/US$) on June
13th, 2012. The analysis for Vietnam showed that direct
medical costs were approximately: per case without staff
costs 43 US$; per outpatient 27 US$; per adult general
ward inpatient 53 US$; per child general-ward inpatient
46 US$; per ICU patient 108 US$. Harving et al. (2007)
[9] found similar direct costs (32 US$, that would
roughly match our findings if accounting for inflation
between 2007 to 2012) and established a ratio of direct
versus indirect costs (US$ 32 direct cost to US$ 29 indir-
ect costs). We applied the same ratio to our findings.
Other cost components in Vietnam were: government
budgets for vector control 5,285,280 US$, or 44%; sur-
veillance 1,029,600 US$, or 9%; and IEC (information,
education and communication, 549,120 US$, or 5%.
When adding these to the direct (2,700,138 US$ or 22%)
and indirect cost (2,447,000 US$ or 20%), we estimated
that the outbreak costs for Vietnam in 2011 were around
13 million US$ with 69,680 dengue patients reported
(Figure 1).
Indonesia
Indonesia collected costs for six patient groups: a typical
dengue outpatient (separately for adult and child); a
16%
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4%
43%
35%
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Vector control
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Figure 3 Cost components during dengue outbreaks in Peru. All in US$ of the year 2011; Vector control: 738,701 US$ (16%); Surveillance:
112,024 US$ (2%); IEC: 173,842 US$ (4%); Direct cost: 1,917,791 US$ (43%); Indirect cost: 1,569,102 US$ (35%).
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child), and a typical intensive-care-unit patient (separ-
ately for adult and child). The exchange rate used was
9,523 Rupiah/US$ on August 15th, 2012 (Table 2).
The number of dengue patients during the last out-
break in Indonesia in 2011 could not be estimated be-
cause there was no official definition of an outbreak with
a defined start and end-point, and only dengue haemor-
rhagic fever patients were reported. However, in the re-
cent Jakarta outbreak 17,776 patients were reported.
Although no reliable estimate of the distribution of den-
gue patients in the different treatment settings listed in
the table above could be derived, we used the propor-
tions of outpatients versus general-ward inpatients ver-
sus intensive care patients established in Vietnam, that
was 55% versus 35.1% versus 9.9% respectively. We
obtained an estimate of total treatment costs (3,288,200
US$ or 49%) in the Jakarta outbreak, which was the sum
of 53,800 US$ for outpatients, 1,085,700 US$ for general
ward patients and 2,148,700 US$ for intensive care pa-
tients. However, an estimate of public sector cost in the
outbreak area was available: Surveillance was estimated
to amount to 13,722 US$ (or 0.2%), vector control to
465,676 US$ (or 6.8%) and information, education and
communication to 2,927 US$ (or 0.04%). When applyingthe findings in Vietnam (where indirect costs were
around 90% of the direct cost) to Indonesia we obtain
indirect costs of 2,979,902 US$ or 44% (Figure 2).
Peru
Resource utilization for the “typical” dengue patient,
with indication of the probability of item usage, was col-
lected in four different hospitals in Peru: Hospital de
Apoyo Iquitos, Hospital Regional Iquitos, Hospital Tara-
poto and Hospital Solidaridad. We calculated cost in
Nuevo Sol (PEN) 2012 and used an exchange rate (PEN/
US$) of 2.678 on June 13th, 2012. The number of total
cases in Iquitos came to 24,506, of which 21,740 were
outpatients, 2,635 were inpatients in general wards and
131 were intensive-care-unit patients. The number of
cases in each category was based on dengue without or
with warning signs, and severe dengue. The proportion
of adults (>15 years) was estimated to be 40% in outpa-
tients, 50% in general wards and 30% in the ICU setting.
We found that direct treatment costs per patient with-
out staff cost amounted to 78 US$ (in 2012 US$) in
Peru. Based on Shepard et al. (2011) [3], we assumed a
proportion of 55 to 45 per cent direct-to-indirect costs
in Peru and calculated total direct and indirect cost of
142 US$ per patient. This corresponds to 37% of the
0%
51%
49%
Dominican Republic
Vector control
Surveillance
IEC
Direct Cost
Indirect Cost
Figure 4 Cost components during dengue outbreaks in Dominican Republic. All in US$ of the year 2011; Vector control: 9,165 US$ (0%);
Surveillance: 2,550 US$ (0%); IEC: NA; Direct cost: 1,424,007 US$ (51%); Indirect cost: 1,367,047 US$ (49%).
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[3], which might include other cost items, such as staff
costs and direct non-medical costs. Surveillance, vector
control and IEC budgets were collected for the study
area in Peru (region San Martin and Loreto). The gov-
ernment expenditures were: for vector control 738,701
US$, or 16%; for surveillance 112,024 US$, or 2%; and
for IEC 173,842 US$, or 4%. Adding this to the direct
(1,917,791 US$ or 43%) and indirect cost (1,569,102 US$
or 35%), we estimated that the total cost of the Iquitos
outbreak in 2011 came to around 4.5 million US$
(Figure 3).
Dominican Republic
In the Dominican Republic 12,171 dengue patients were
reported during the outbreak in 2011, of which 292 were
outpatients, 11,864 were general-ward patients and 15
were intensive-care patients. In the general ward 68% of
patients were adults, and 32% were children (<15 years).
The exchange rate used for the analysis was 39.03 DOP/
US$ on June 17th, 2012. For the Dominican Republic,
hospital records of 5 outpatients, 9 adult general-ward
patients, 28 child general-ward patients, and 15 ICU pa-
tients were analysed in terms of resource identification,
quantification and valuation. The average direct cost percase without personal costs amounted to 117 US$ in
2012. Shepard et al. (2011) [3] obtain a ratio of indirect
to direct cost of 96% for the Dominican Republic. The
corresponding indirect cost estimation based on our dir-
ect cost estimate is 112 US$. Shepard et al. (2011) [3]
obtained a weighted average estimation of total costs of
430 US$ per dengue case based on their economic
model. The cost we obtained for government spending
on vector control was a total of 9,165 US$ per year on
average over the years 2009 to 2012. Cost for collecting,
storing, analysing and communicating surveillance data
amounted to 2,550 US$. Our total cost estimate was
around 2.8 million US$ (Figure 4).
Discussion and conclusions
Evidence from the systematic literature review
Limitations and comparability of publications
This review included only publications in the given data-
bases within the given time period: 1966 to April 1st
2012. Unpublished data, evaluations, dissertations and
books were not included. Publications in Spanish,
Portuguese and English were included.
The comparability of the reviewed studies was restricted
due to variations in the perspective taken to collect costs,
the definition and reporting of costs, and the inclusion or
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proach. Finally, precise details on the year of cost account-
ing (year of prices), the exchange rate used and the
transformations conducted to calculate costs (discounting,
inflation adjustment) were missing. The Asian countries
had been neglected in terms of methodologically compar-
able cost of illness studies as produced by Shepard et al.
[3] for the Americas. Sensitivity analyses would increase
the validity of produced cost figures.
Moreover, the calculation of dengue costs posed tech-
nical problems. Under- and over-reporting of dengue
cases made the exact number of dengue cases uncertain,
even after correcting with an expansion factor. For ex-
ample the average expansion factor of 2.3 for the Ameri-
cas had a range of 1.4 to 3.3 in a hospitalized setting and
an average of 15 and a range of 9 to 28 in an ambulatory
setting. Moreover the average cost per dengue case var-
ied according to country, treatment (ambulatory, hospi-
talized) and geographical (urban, rural) setting, patient
age and hospital type (private, public) and therefore
should be calculated as a weighted average, in those situ-
ations when the data for each setting is available.
Average total costs per case for all the countries in the
Americas based on the costs collected and modelled by36%
32%
Average Costs of Deng
Figure 5 Total cost components in percent estimated for a recent de
technical services, drugs, consumables, fees and other resources. Indirect co
control: 6,498 US$ (25%); Surveillance: 1,157 896 US$ (4%); IEC: 725, 889 (3%Shepard et al. 2011 [3] showed the important variations
in costs between countries studied. Average costs per
case in the Americas was given as 571 US$, with a 95%
confidence interval of 362 to 752 US$, illustrating the
important variation between countries. On average, the
share of indirect costs to total costs amounts to 60%
(40% direct costs), but there is also large variation be-
tween countries in the Americas. Moreover, depending
on the year considered, the cost of dengue could vary,
which was very well illustrated by Shepard et al. 2011
[3], but had been neglected by prior cost of illness stud-
ies in dengue, which did not average costs over several
successive years. Finally, variations in total costs were
substantial depending on the assumed expansion factor,
and the share of hospitalized cases or average ambula-
tory cost per case - varied from 1 to 4 billion US$ in the
Americas according to Shepard et al. 2011 [3].
Cost and cost-effectiveness of Interventions
Only one paper from Baly et al. [12] addressed the costs
of outbreaks explicitly and, to our knowledge, methodo-
logically accurately in a prospective study. All other pa-
pers in group A investigated cost of illness with very
different methodological approaches, and so faced25%
4%
3%
ue
Vector control
Surveillance
IEC
Direct Cost
Indirect Cost
ngue outbreak in four countries. Direct costs include laboratory,
sts include loss of working hours. All in US$ of the year 2011; Vector
); Direct cost: 9,330,104 US$ (36%); Indirect cost: 8,363,051 US$ (32%).
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http://www.biomedcentral.com/1471-2458/13/1048various technical challenges which need to be addressed
in best practice research guidelines. Comparability of the
reviewed papers was very limited and, accordingly, a dir-
ect comparison between countries was not very mean-
ingful, except in papers with a consistent methodology
applied to different countries. Only one paper dealt with
modelling the unforeseen cost of cutting the budget for
dengue disease surveillance and response, which would
be interesting for future modelling research on the cost-
effectiveness of improved surveillance systems. More-
over, methods were available and had been applied to in-
terventions in the field of dengue prevention and control
to calculate cost-effectiveness ratios.
Evidence from the country case studies
No data on cost of dengue outbreaks had been published
for Vietnam, Indonesia, Dominican Republic and Peru
(Figures 1, 2, 3, 4 and 5). Our data provided the first esti-
mates of the potential economic impact of dengue out-
breaks in these countries. Further research, in particularly
prospective studies, is needed to make these estimates
more robust.
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